U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business
Lee Jae Myung, Trump Discuss Step-by-Step North Korea Nuclear Strategy at G7
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Pakistan, Qatar Mediation Secures Preliminary U.S.-Iran Deal Amid High-Stakes Negotiations
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions
U.S.-Iran Talks in Switzerland Postponed as Questions Over Interim Deal Persist
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million
Trump Says Anthropic No Longer Seen as National Security Threat
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace
US Military Says Strait of Hormuz Remains Open Despite Iran Closure Claim
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 



